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One of the most powerful ways to test the function of
a protein is to characterize the consequences of its
deletion. In the past, this has involved inactivation
of the gene by homologous recombination either in
the germline or later through conditional deletion.
RNA interference (RNAi) provides an alternative
way to knock down proteins, but both of these
approaches have their limitations. Recently, the
CRISPR/Cas9 system has suggested another way
to selectively inactivate genes. We have now tested
this system in postmitotic neurons by targeting two
well-characterized synaptic proteins, the obligatory
GluN1 subunit of the NMDA receptor and the
GluA2 subunit of the AMPA receptor. Expression of
CRISPR/Cas9 in hippocampal slice cultures com-
pletely eliminated NMDA receptor and GluA2 func-
tion. CRISPR/Cas9 thus provides a powerful tool to
study the function of synaptic proteins.
INTRODUCTION
Historically, pharmacology provided most of the initial insight
into function of central synapses. Selective antagonists for
neurotransmitter receptors, which have the advantage of rapid
and reversible actions, established the role of AMPA and
NMDA receptors in synaptic transmission and plasticity (Colling-
ridge et al., 1983; Hestrin et al., 1990; Watkins et al., 1990). For
most of the myriad proteins in the postsynaptic density, how-
ever, a pharmacological approach has not been possible. The
introduction of gene targeting in embryonic stem (ES) cells al-
lowed the production of mice in which specific genes are deleted
(Capecchi, 1989; Silva et al., 1992). This technology enabled
many advances in vertebrate biology including neuroscience
but suffers from two limitations. First, the gene deletion is global
and in many cases lethal. Second, the deletion occurs in the
germline, raising the possibility of compensation during develop-
ment. The introduction of conditional knockout (KO) technology
has circumvented some of these problems (Adesnik et al., 2008;
Plu¨ck, 1996; Sauer and Henderson, 1988; Tsien et al., 1996). InNethis approach, the selective expression of Cre recombinase
restricts gene deletion to those cells expressing Cre. This
approach nonetheless requires the production of conditional
KOmice, involving considerable time and expense. RNA interfer-
ence (RNAi) provides a more facile way to knock down protein
expression (Ehrlich and Malinow, 2004; Elias et al., 2006; Fire
et al., 1998; Futai et al., 2007; Hannon, 2002) but has its own lim-
itations. Off-target effects can occur (Alvarez et al., 2006; Per-
sengiev et al., 2004). Although this problem can be addressed
by rescuing the loss of function with an RNAi-resistant construct,
the lack of effect in an animal lacking the gene is even more
definitive. More important, however, RNAi rarely eliminates the
protein, making it difficult to determine whether any residual
function reflects residual protein or an unrelated process.
New genome editing approaches have recently been devel-
oped that have the potential to circumvent many of the prob-
lems associated with homologous recombination in ES cells
and RNAi (Wijshake et al., 2014). These include TALENs, zinc
finger nucleases, and more recently clustered regularly inter-
spaced short palindromic repeats (CRISPR). Originally discov-
ered in bacteria as an adaptive immune defense mechanism
against viral attack, CRISPR has now been developed for
gene editing, such as deleting, silencing, enhancing, or chang-
ing specific genes in eukaryotes (Canver et al., 2014; Cong
et al., 2013; Hsu et al., 2014; Mali et al., 2013; Perez-Pinera
et al., 2013; Qi et al., 2013; Yang et al., 2013). The expression
of nuclease Cas9 along with specifically designed guide RNAs
enables the genome to be cut at virtually any location (Ran
et al., 2013b).
In previous work, we and others have used genetic manipula-
tion in single cells of hippocampal slice culture to study the role
of specific postsynaptic proteins in synaptic transmission (Ades-
nik et al., 2008; Hayashi et al., 2000; Schnell et al., 2002). This
approach requires the sparse transfection of pyramidal neurons,
by either biolistics or viral infection. After a period of time, the
afferent fibers to a transfected cell and untransfected neighbor
(as control) are stimulated and the postsynaptic responses
compared. The direct simultaneous comparison of transfected
and control cells increases the power of this system to identify
functionally important differences.
To assess the ability of the CRISPR/Cas9 system to delete
specific synaptic proteins, we focused on two proteins easily
amenable to measurement. Excitatory synapses express twouron 83, 1051–1057, September 3, 2014 ª2014 Elsevier Inc. 1051
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Figure 1. Deletion of NMDA Currents by CRISPR/Cas9 Knockout of
GRIN1
(A) Sample traces of NMDAR evoked EPSCs, from a transfected CRISPR/
Cas9 cell (green trace) and a neighboring control cell (black trace) in the
presence of NBQX (10 mM) and after addition of D AP-5 (50 mM). (B) Bar graph
showing the averaged eEPSC amplitudes of control, 46.43 ± 4.22 pA, n = 9;
CRISPR_GRIN1, 0 pA, n = 9; control + AP-5, 0 pA, n = 5; CRISPR_GRIN1+ AP-
5, 0 pA, n = 5. (C) Western blot for the GluA2 subunit of the AMPAR and GluN1
subunit of the NMDAR of 18-day-old dissociated hippocampal neurons in-
fected with lentiCRISPR_GRIN1 or lentiCRISPRGRIA2 on day 4. (D) Types and
frequency of insertions or deletions obtained after infecting dissociated hip-
pocampal neurons with lentiCRISPR GRIN1. See also Figure S1.
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Studying Synaptic Proteins with CRISPR/Cas9types of glutamate receptor: NMDA receptors (NMDARs) and
AMPA receptors (AMPARs). NMDARs are composed of two
essential GluN1 subunits and two GluN2 subunits. After the
removal of GluN1 by CRISPR/Cas9, we indeed detected no
NMDAR-mediated currents. AMPARs are composed of four
subunits, GluA1–GluA4, that contribute to the formation of het-
erotetrameric receptors. Most AMPARs contain the GluA2 sub-
unit, which has a profound effect on the biophysical properties
of the receptor: in the presence of GluA2, the receptor is imper-
meable to calcium and the current-voltage (IV) relationship is
linear; in the absence of GluA2, AMPA receptors are permeable
to calcium and exhibit strong inward rectification (Jonas and
Burnashev, 1995). We have thus used the I-V relationship to
assess GluA2 subunit content after inactivation of GluA2 by
CRISPR/Cas9.1052 Neuron 83, 1051–1057, September 3, 2014 ª2014 Elsevier Inc.RESULTS
Deletion of GluN1
We first coated gold particles with a vector encoding Cas9 as
well as guide RNAs (gRNAs) targeting the GluN1 subunit of the
NMDAR (see Experimental Procedures). These particles were
biolistically delivered to hippocampal slice cultures and record-
ings made 14 days later from a transfected cell and simulta-
neously from a neighboring control cell. The AMPAR antagonist
NBQX was used so that NMDAR-mediated excitatory postsyn-
aptic currents (NMDAR EPSCs) could be recorded in isolation.
Figure 1A shows a sample pair of recordings. Stimulation elicited
a large NMDAR EPSC in the control cell (black trace) but no cur-
rent in the transfected cell (green trace). Subsequent application
of the NMDAR antagonist AP-5 abolished the response in the
control cell and had no further effect in the transfected cell, indi-
cating that CRISPR had eliminated the NMDAR EPSC. A sum-
mary of all the recordings indicates that cells expressing CRISPR
for 14 days invariably lacked NMDAR EPSCs (Figure 1B). The
physiological records thus suggest that CRISPR has deleted
the GluN1 protein from all these cells. To confirm the loss of
NMDAR, we expressed CRISPR/Cas9 in dissociated neuronal
cultures using a lentiviral construct and measured receptor
expression in these neurons by western analysis 14 days later.
As anticipated from the physiology, CRISPR/Cas9 effectively
deleted the GluA2 and GluN1 proteins, but the expression of
b-actin and synaptophysin was not affected (Figure 1C). We
also analyzed the types and frequency of mutations obtained
when targeting GRIN1 with CRISPR in our dissociated neuronal
cultures. The most common (5 out of 11) mutation that we
identified is a 2 bp deletion that occurred 1 bp upstream of the
cleavage site. We also found two 1 bp insertions, two other
2 bp deletions, a 3 bp deletion, as well as a bigger 19 bp deletion.
Interestingly, >90% of the mutations led to out-of-frame inser-
tions or deletions (Figure 1D).
Deletion of GluN1 by Cre recombinase in conditional KO mice
produces a substantial increase in AMPAREPSCs (Adesnik et al.,
2008; Gray et al., 2011; Ultanir et al., 2007). To determine whether
the deletion of GluN1 by CRISPR reproduces this effect, we
repeated the experiments as above but omitted NBQX to mea-
sure the AMPAR as well as NMDAR EPSC. To measure the
AMPAR EPSC, we held the cell at 70 mV (Figure 2D), but for
the NMDAR EPSCwe held the cell at +40 mV, measuring the cur-
rent 100 ms after the stimulus when the AMPAR EPSC had re-
turned to baseline (Figure 2A, dotted line). As shown in Figure 1,
theNMDARcomponent of the evoked EPSCwas entirely blocked
(Figures 2A and 2B). We also determined the time course of this
effect and found that by 5 days, the NMDAR EPSC was reduced
by 60%, and by 12 days, it was absent (Figure 2C). Over this
period, the AMPAR EPSC increased approximately 2-fold (Fig-
ures 2D and 2E). However, the time course of this increase was
delayed relative to the decline in NMDAR EPSC and continued
to increase even at 15 days (Figure 2F). Finally, we examined
paired-pulse facilitation, which is a sensitivemeasure for changes
in the presynaptic probability of transmitter release (Figure S2
available online). As anticipated from previous work (Adesnik
et al., 2008; Gray et al., 2011), the change in glutamate receptor
expression did not affect release probability. To test the
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Figure 2. Deletion of NMDAR by CRISPR/Cas9 Increases AMPAR EPSCs
(A) Scatterplot shows amplitudes of NMDA EPSCs for single pairs (open circles) and mean ± SEM (filled circle) for GRIN1 KO by CRISPR/Cas9. Data represent
pairs of simultaneously recorded neurons in slice culture fromCRISPR_GRIN1-transfected and neighboring control cells 14–15 days after transfection. Scale bar,
50 pA and 50ms. (B) Paired average of single pairs from control and transfected cells. Mean ± SEM for control and CRISPR_GRIN1 are 37.53 ± 4.7 pA, n = 16 and
2 ± 0.8 pA, n = 16, respectively. ***p = 0.0005 Wilcoxon signed-rank test. The very small remaining current measured at 100 ms is due to a small residual tail of
AMPAR current. (C) Time course for the changes in NMDAR EPSC amplitudes in hippocampal slice cultures after CRISPR_GRIN1 transfection. This includes data
in the absence of NBQX (5 days and 7 days) and in the presence of NBQX (10 days, 12 days, and 15 days). The values represent the percentage of control for
different days following transfection: 5 days 46.3% ± 7%, n = 10; 7 days 40.6% ± 8%, n = 8; 10 days 2.8% ± 1.8%, n = 8; 12 days 0% ± 0%, n = 8; 15 days 0% ±
0%, n = 9. (D) Scatterplot for AMPAR EPSC amplitudes for single pairs (open circles) and mean scatterplot (filled circle). Scale bar, 50 pA and 50 ms. (E) Paired
average of single pairs from control and transfected CRISPR_GRIN1 cells. Mean ± SEM for control and transfected neurons are 105 ± 13.5 pA n = 16 and 281.2 ±
41 pA n = 16, respectively. ***p = 0.0001 Wilcoxon signed-rank test. (F) Time course for the changes in AMPAR EPSC amplitudes in hippocampal slices after
CRISPR_GRIN1 transfection. Ratio of AMPAR EPSC: 5 days 167.7% ± 25.8%, n = 10; 7 days 230.2% ± 13.2%, n = 8; 10 days 310% ± 42%, n = 13; 12 days
302% ± 87%, n = 11; 15 days 359% ± 69%, n = 16. See also Figure S2.
Neuron
Studying Synaptic Proteins with CRISPR/Cas9reproducibility of this approach, we also designed another gRNA
that targets a different sequence of GluN1 and observed identical
effects (Figure S1). The results show that deletion of GluN1 using
CRISPR/Cas9 has effects identical to the deletion of GluN1medi-
ated by cre recombinase in conditional KO mice (Adesnik et al.,
2008; Gray et al., 2011; Ultanir et al., 2007).
Since off-target effects are of concern with the CRISPR/Cas9
system (Fu et al., 2013; Pattanayak et al., 2013), we designed a
gRNA that encompasses an intron-exon junction of the GluN1
coding region (see Experimental Procedures). This gRNA should
not target the NMDAR cDNA and would thus enable simple
rescue experiments using anNMDARexpression vector. Indeed,
we found that expression of this gRNA sequence efficiently elim-
inated NMDAR EPSCs (Figure S1) and that cotransfection of
NMDAR cDNA completely rescued the NMDAR EPSC (Figures
3A and 3B). It also eliminated the effect of GluN1 deletion onNeAMPAR EPSC (Figures 3B and 3C), showing that both of these
effects are indeed due to the selective targeting of GluN1.
Furthermore, to demonstrate that an unrelated cDNA does not
rescue the effect of GluN1 CRISPR disruption unspecifically,
we cotransfected a p-CAGG-IRES mCherry cDNA together
with the FUGW GFP and CRISPR_GRIN1. Under these condi-
tions, the GluN1 deletion is also complete, excluding the possi-
bility that the GluN1 rescue is caused by a lower transfection
efficiency of the Cas9/gRNA components (Figure S3). In Fig-
ure S3C, we also show confocal stack images of a neuron ex-
pressing both p-CAGG-mCherry and FUGW-GFP from a
14 day transfected slice. The morphology is that of a typical
healthy pyramidal neuron. As a confirmation of the healthy state
of the transfected neurons, we also measured the input resis-
tance and found no difference between control and transfected
neurons.uron 83, 1051–1057, September 3, 2014 ª2014 Elsevier Inc. 1053
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Figure 3. Rescue of NMDAR EPSC with
GluN1 cDNA Resistant to Cas9
(A) NMDAR EPSC amplitudes of control and
neighboring rescued GluN1 cells, for single pairs
(open circles) and mean ± SEM (filled circle). Scale
bar, 50 pA and 50 ms. (B) Paired average of single
pairs from control and transfected cells. Mean ±
SEM for control and rescue are 37.8 ± 2.8 pA, n =
16 and 38.1 ± 4.9 pA, n = 16, respectively. p = 0.84
Wilcoxon signed-rank test. (C) AMPAR EPSC am-
plitudes for single pairs and mean ± SEM. Scale
bar, 50 pA and 50 ms. (D) Paired average of single
pairs from control and transfected cells. AMPAR
EPSC amplitudes for control and rescue are 87.6 ±
8.1 pA, n = 15 and 86.53 ± 11.56 pA, n = 15,
respectively. Mean ± SEM, p = 0.96 Wilcoxon
signed-rank test. See also Figure S3.
Neuron
Studying Synaptic Proteins with CRISPR/Cas9We have also tried the double nicking approach using the
D10A mutant nickase Cas9 together with a pair of offset gRNAs
complementary to opposite strands of the target site, which has
been proposed to improve specificity (Ran et al., 2013a). How-
ever, we found that this approach is not as efficient as the
Cas9 endonuclease in our experimental conditions (Figures
S1E and S1F).
Deletion of GluA2
CRISPR/Cas9 can delete GluN1 using two independent se-
quences, but will the approach work for other synaptic proteins?
AMPARs are heterotetramers that comprise various combina-
tions of GluA1–Glu4 subunits. In CA1 hippocampal pyramidal
cells, all receptors contain the GluA2 subunit (Lu et al., 2009).
GluA2-containing receptors have a linear current-voltage (I-V)
relationship such that the magnitude of current flow through
the receptor is the same at negative and positive potentials. In
contrast, receptors lacking the GluA2 subunit rectify strongly
such that little outward current flows through the receptor at pos-
itive potentials. Thus, inward rectification provides a sensitive
measure of GluA2 content in the AMPAR. Using two different
gRNAs (GRIA2#1 and GRIA2#2, see Experimental Procedures),
we found that CRISPR_GRIA2 knockout in transfected cells
reduced AMPAR eEPSC (Figures 4A and 4B) and the remaining1054 Neuron 83, 1051–1057, September 3, 2014 ª2014 Elsevier Inc.AMPAR currents were entirely inwardly
rectifying (Figures 4C and 4D), confirming
the results of GluA2 deletion by Cre re-
combinase in conditional KO mice (Lu
et al., 2009). This result is expected from
the strong reduction in GluA2 protein ex-
pression shown in Figure 1C. We also
observed that NMDAR eEPSCs did not
change (Figures 4E and 4F), further con-
firming the specificity of the GluA2
deletion.
To address possible off-target effects
of the CRISPR_GRIA2 knockout, we de-
signed a rescue experiment. Similar to
the GRIN1#2 gRNA, the GRIA2#1 gRNA
encompasses an intron-exon junction ofthe GluA2 gene (see Experimental Procedures). Thus, we used
a cDNA that expresses the edited form of the GluA2 subunit in
order to rescue the inward rectification observed in the GRIA2
KO. Indeed, the cotransfection of CRISPR_GRIA2#1 and of the
GluA2 cDNA eliminated the AMPAR eEPSC reduction observed
in the GRIA2 KO (Figures S4A and S4B) and largely rescued the
inward rectification index (Figures S4C and S4D).
DISCUSSION
We have evaluated the ability of the CRISPR/Cas9 system to
delete synaptic proteins. For these experiments, we first
focused on the GluN1 subunit. Since the GluN1 subunit is
required for NMDAR function, the size of the NMDAR EPSC pro-
vides a sensitive measure of GluN1 expression. Indeed, we
found that coexpression of gRNAs to GluN1 together with
Cas9 in hippocampal pyramidal cells gradually reduced the
size of the NMDAR EPSC and by 12 days after transfection no
NMDAR function could be detected. Importantly, we completely
rescued the NMDAR EPSC by expressing a GluN1 cDNA resis-
tant to the action of intron-directed CRISPR/Cas9. To determine
whether the CRISPR/Cas9 system could be used for other syn-
aptic proteins, we turned to the GluA2 subunit of the AMPAR.
AMPARs are heterotetrameric receptors and those expressed
A B
C D
E F
Figure 4. CRISPR/Cas9 GRIA2 Knockout
(A) AMPAR EPSC amplitudes of control and
neighboring GRIA2 KO by CRISPR/Cas9. Scat-
terplot for single pairs (open circles) and mean ±
SEM (filled circle). Scale bar, 50 pA and 10 ms. (B)
Graph bars represent mean values of AMPAR
EPSC amplitudes for control and CRISPR_GRIA2.
Mean ± SEM are Cnt 101.6 ± 13 n = 11;
CRISPR_GRIA2 39.7 ± 4.4 n = 11. **p = 0.001
Wilcoxon signed-rank test. (C) Graph representing
I/V plots for control and CRISPR_GRIA2 cells: the
AMPAR EPSC from the GluA2 KO cell is inwardly
rectifying. (D) Mean ± SEM of rectification index
values for control (0.88 ± 0.1) and CRISPR_GRIA2
cells (0.06 ± 0.03). ***p < 0.0001 Student’s un-
paired t test. (E) NMDAR EPSC scatterplot for
single pairs (open circles) and mean ± SEM (filled
circle). Scale bar, 50 pA and 50 ms. (F) Graph bars
represent mean values of NMDAR EPSC ampli-
tudes for control and CRISPR_GRIA2. Mean ±
SEM are Cnt 38.36 ± 5 n = 11; CRISPR_GRIA2
40.8 ± 4 n = 11. p = 0.77Wilcoxon signed-rank test.
See also Figure S4.
Neuron
Studying Synaptic Proteins with CRISPR/Cas9in CA1 pyramidal cells contain the GluA2 subunit. Using inward
rectification to monitor the expression of synaptic GluA2 (Jonas
and Burnashev, 1995), we found that coexpression of gRNAs to
GluA2 along with Cas9 for 12 days resulted in strongly rectifying
AMPAR EPSCs, indicating loss of the GluA2 subunit from
AMPARs.
The CRISPR/Cas9 system has multiple advantages over pre-
vious methods to delete neuronal proteins. Conditional gene
inactivation using cre recombinase provides a similarly complete
loss of gene function. However, the associated genetic manipu-
lation in embryonic stem cells followed by injection of these cellsNeuron 83, 1051–1057, Seinto embryos requires considerable time
and effort, even with recent technical
improvements. The resulting animals
also require at least two generations of
breeding before initial experiments can
be performed, and longer if crossing to
a line that expresses cre recombinase
in specific tissues. The CRISPR/Cas9
system now enables the inactivation of
genes in somatic cells, without the re-
quirement for homologous recombination
in the germline. In the case of GluN1, inac-
tivation occurred within 2 weeks after
transfection.
RNAi can also be performed on a rela-
tively rapid timescale and has been used
for high-throughput experiments such as
genetic screens in vitro and in vivo (Fire
et al., 1998; Hannon, 2002). However, a
major problem associated with RNAi, at
least in most mammalian systems, is
incomplete gene silencing. RNAi rarely
eliminates the protein targeted, and
residual protein makes it very difficultto interpret the resulting phenotype. The phenotypes are often
incomplete or variable, and the lack of phenotype can be
particularly difficult to interpret in the presence of residual pro-
tein. We now find that the CRISPR/Cas9 system works much
more efficiently, with essentially complete loss of the glutamate
receptor subunits targeted. All of the transfected cells in hippo-
campal slice culture failed to express GluN1 after 2 weeks incu-
bation, and the miniscule amounts of residual protein observed
by western analysis from dissociated hippocampal cultures
may simply reflect incomplete infection by the recombinant
virus. The ability to introduce CRISPR/Cas9 into specific cellsptember 3, 2014 ª2014 Elsevier Inc. 1055
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Studying Synaptic Proteins with CRISPR/Cas9also circumvents problems such as lethality associated with
global gene inactivation in knockout mice. The relatively acute
effect of CRISPR/Cas9 further mitigates the potential for
compensation. In addition, it is essential to perform rescue ex-
periments that definitively rule out off-target effects as the
cause of the observed phenotype. For the rescue, it is impor-
tant to ensure that the rescue construct will not itself be tar-
geted by CRISPR. This can be achieved either by using a
cDNA with silent mutations introduced into the region recog-
nized by the gRNA (and/or the PAM) or by using a cDNA
from a different species if there is sufficient divergence in
the sequence. In this study, we performed the rescue experi-
ment using another, simpler approach. Indeed, we searched
for a specific gRNA sequence encompassing an intron-exon
junction such that the cleavage site (position 3) would be in
the exon, but most of the gRNA sequence would lie within
the intron. By using this very simple strategy, it is now possible
to perform rescue experiments using unmodified cDNA,
which greatly simplifies and accelerates the validation of the
phenotype.
It is remarkable that CRISPR/Cas9 so effectively eliminates
the expression of proteins, and this may specifically reflect the
postmitotic nature of neurons. Our sequencing analysis of the
GRIN1 locus identified a series of insertions or deletions that
led to out-of-frame mutations in >90% of the case. This strongly
suggests that the Cas9 nuclease, indeed, produces a double-
strand break that triggers repair, and this nonhomologous end-
joining repair results in gene inactivation. However, there is
some chance that this repair will restore the original sequence.
In dividing cells where the gRNAs and Cas9 are lost through
repeated cell division, repair would prevent gene inactivation,
particularly since only one properly repaired allele may suffice
for a wild-type phenotype. In contrast, the persistent gRNAs
and Cas9 nuclease in postmitotic neurons might continue to
cleave any properly repaired sequence, resulting in eventual
incorrect repair and inactivation of both alleles. Another possibil-
ity to consider is that the repair following the Cas9 double
strained break, although not perfect, fails to silence the gene
and Cas9 also fails to recognize the imperfectly repaired
sequence. In this case, one would expect a transfected neuron
without physiological phenotype. This scenario does not appear
to have happened in our experimental sample. In a total of 107
experiments, we did not encounter a cell in which the function
of the targeted protein remained unaltered after the expression
of Cas9 and a gRNA. Regardless of mechanism, CRISPR/Cas9
appears remarkably effective in neurons and holds great prom-
ise for understanding the molecular underpinning of synaptic
plasticity.EXPERIMENTAL PROCEDURES
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